(NASDAQ: HOWL) Werewolf Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.82%.
Werewolf Therapeutics's earnings in 2026 is -$60,822,000.On average, 7 Wall Street analysts forecast HOWL's earnings for 2026 to be -$57,004,066, with the lowest HOWL earnings forecast at -$81,438,546, and the highest HOWL earnings forecast at -$37,249,460. On average, 5 Wall Street analysts forecast HOWL's earnings for 2027 to be -$79,062,162, with the lowest HOWL earnings forecast at -$104,774,737, and the highest HOWL earnings forecast at -$50,516,391.
In 2028, HOWL is forecast to generate -$72,866,067 in earnings, with the lowest earnings forecast at -$97,631,005 and the highest earnings forecast at -$45,413,725.